Difference between revisions of "Establishing a novel neural tissue deformation biomarker for type 1 chiari malformation"

From niml.org
Share/Save/Bookmark
 
 
(12 intermediate revisions by 2 users not shown)
Line 1: Line 1:
[[Image:mri_adult.jpg|thumb|right|400px|Figure 1. MR measurement of the cerebrospinal fluid spaces in a healthy adult female.]]
+
[[File:Chiari_MR.jpg | thumb | right | MR measurement of Chiari patient.]]
  
  
 
==Team==
 
==Team==
 
*[[Bryn Martin]]
 
*[[Bryn Martin]]
 +
*[[Gwendolyn Williams]]
  
 
==Problem==
 
==Problem==
Here.
+
 
 +
Untreated Type 1 Chiari malformation (CM1) is a devastating neurological disorder that can be treated by a high risk and costly brain operation. Since the decision to operate is often based on common symptoms, such as severe headache, along with a single imaging measure of cerebellar position that is commonly recognized as inadequate, the concern for under- and especially over-treatment is high. With an estimated 4-5 million in the US carrying the current inadequate anatomical marker of cerebellar descent >5 mm below the foramen magnum, and approximately 97% of these millions demonstrating only minimal symptoms or symptoms with other unrelated etiologies, there is a potential for tens of thousands of inappropriate operations with corresponding bad outcomes, while others suffer untreated. The CM1 public critically needs a biomarker that better reflects CM1 pathophysiology, allowing physicians a more accurate surgical selection.
  
 
==Study Information==
 
==Study Information==

Latest revision as of 22:08, 4 August 2020

MR measurement of Chiari patient.


Team

Problem

Untreated Type 1 Chiari malformation (CM1) is a devastating neurological disorder that can be treated by a high risk and costly brain operation. Since the decision to operate is often based on common symptoms, such as severe headache, along with a single imaging measure of cerebellar position that is commonly recognized as inadequate, the concern for under- and especially over-treatment is high. With an estimated 4-5 million in the US carrying the current inadequate anatomical marker of cerebellar descent >5 mm below the foramen magnum, and approximately 97% of these millions demonstrating only minimal symptoms or symptoms with other unrelated etiologies, there is a potential for tens of thousands of inappropriate operations with corresponding bad outcomes, while others suffer untreated. The CM1 public critically needs a biomarker that better reflects CM1 pathophysiology, allowing physicians a more accurate surgical selection.

Study Information

We are currently enrolling subjects for this study. This study involves 1 non-invasive MRI scan at Inland Imaging in Spokane, WA. Subjects with diagnosed ALS and age/gender matched controls are needed. Participants must be able to lay on their back in the MRI scanner for the 1-hour scanning period. We can provide the MR images to participants free of charge. Please click on the links below to learn more.